BiSTC Portfolio - Our Trials in More Detail

BiSTC trials portfolio  - our open trials are listed below.  Please follow the hyperlinks to the specific trials websites which contain further information about each study and who to contact. 

Table of open trials in the BiSTC portfolio

 ACCURE-UK-Logo_5

 

ACCURE UK:  The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis - The ACCURE-UK Trial Feasibility study

Speciality: IBD

Chief Investigator: Professor Thomas Pinkney

Funded By: RfPB     Portfolio Study ID: 17515

Phase: Pilot/Feasibility

Initial Target Number of Patients: 48

 ACCURE-UK_2-Logo

ACCURE-UK 2:  An international multicentre randomised controlled trial to assess the effect of Appendectomy on the Clinical Course of UlceRativE colitis; UK Arm

Speciality: IBD

Chief Investigator: Professor Thomas Pinkney

Funded By: EME   Portfolio Study ID: 40580

Phase: Phase III

Initial Target Number of Patients: 90

AceticA Logo

AceticA:  A clinical trial looking at the efficacy and optimal dose of acetic acid in burn wound infections

Speciality: Burns         

Chief Investigator: Mr Naiem Moiemen

Funded By: SRMRC   Portfolio Study ID: 36451

Phase: Phase II            

Initial Target Number of Patients: 20

 ADaPT Logo

ADaPT:  Androgen precursor Dehydroepiandrosterone Pharmacokinetics in Trauma

Speciality:  Trauma     

Chief Investigator: Lt Col Mark Foster

Funded By: SRMRC  Portfolio Study ID: N/A

Phase: Phase II            

Initial Target Number of Patients: 270

 AdUP_Logo

AdUP:  A trial looking at a biological therapy to treat prostate cancer that has come back after radiotherapy and hormone therapy

Speciality: Prostate Cancer

Chief Investigator: Mr Prashant Patel

Funded By: MRC/Department of Health  Portfolio Study ID: 13599

Phase: Phase I     

Initial Target Number of Patients: 15

 BASIL-2-Logo-Cropped-175x175

BASIL-2:  Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a ‘vein bypass first’ with a ‘best endovascular treatment first’ revascularisation strategy for severe limb ischaemia due to infra-popliteal arterial disease

Speciality: Vascular

Chief Investigator: Professor Andrew Bradbury

Funded By: HTA     Portfolio Study ID: 16699

Phase: Phase III     

Initial Target Number of Patients: 600

 BASIL-3-Logo_100x100

BASIL-3:  Multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and plain balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease

Speciality: Vascular

Chief Investigator: Professor Andrew Bradbury

Funded By: NIHR    Portfolio Study ID: 19816

Phase: Phase III     

Initial Target Number of Patients: 861

 

BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Speciality: Brain    Chief Investigator: Prof Darren Hargrave

Funded By:  CRUK     Portfolio Study ID: N/A

Phase:  Phase II  

Initial Target Number of Patients: 80

 CHEETAH Logo

CHEETAH:  Cluster randomised trial of sterile glove and instrument change at the time of wound closure to reduced surgical site infection. A trial of low and middle income countries (LMICs)

Speciality: General Surgery  

Chief Investigator: Professor Dion Morton & Professor Peter Brocklehurst

Funded By: Global Surgery     Portfolio Study ID: N/A

Phase: Phase III     

Initial Target Number of Patients: 600 (pilot), 12,800 (main)

 CompARE

compARE:  Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: CRUK     Portfolio Study ID: 18621

Phase: Phase III     

Initial Target Number of Patients: 650

 CReST-logo-2189x185

CReST:  The role of endoluminal stenting in the acute management of obstructing colorectal cancer

Speciality: Colorectal  

Chief Investigator: Professor James Hill

Funded By: CRUK     Portfolio Study ID: 4708

Phase: Phase III     

Initial Target Number of Patients: 500

 CReST2-Logo

CREST-2: ColoRectal Stenting Trial 2 - Uncovered vs covered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting.

Speciality: Colorectal        

Chief Investigator: Professor James Hill

Funded By: NIHR HTA     Portfolio Study ID: 32120

Phase:  Phase III    

Initial Target Number of Patients: 350

 

DESKTOP

III

DESKTOP III:  A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer

Speciality: Ovarian Cancer

Chief Investigator: Professor David Luesley

Funded By: CTAAC     Portfolio Study ID: 11498

Phase: Phase III     

Initial Target Number of Patients: 100


EAGLE Logo

EAGLE: Safe-anastomosis Programme in Colorectal Surgery

Speciality: Colorectal  Chief Investigator: Professor Dion Morton

Funded By: ESCP       Portfolio Study ID: N/A

Phase: N/A    Initial Target Number of Patients: 4400

 ElaTION-Logo

ElaTION:  The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: HTA     Portfolio Study ID: 17373

Phase: Phase III     

Initial Target Number of Patients: 1000

 ENDCaP-C logo

ENDCaP-C:  Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study

Speciality: IBD

Chief Investigator: Professor Tariq Iqbal

Funded By: NIHR EME      Portfolio Study ID: 17739

Phase: Phase III      

Initial Target Number of Patients: 1000

 EPIVIN

EPIVIN:  A trial of Veregen cream for women with vulval intraepithelial neoplasia 

Speciality: Gynaecology Cancer

Chief Investigator: Professor David Luesley

Funded By: NIHR EME     Portfolio Study ID: 15759

Phase: Phase II     

Initial Target Number of Patients: 56

 FALCON (31-Jan-20)

FALCON: Pragmatic multicentre FActorial randomised controlled triaL testing measures to reduCe surgical site infection in lOw and middle income couNtries

Speciality: Colorectal               

Chief Investigator: Professor Dion Morton

Funded By: Global Surgery     Portfolio Study ID: N/A

Phase: Phase III                        

Initial Target Number of Patients: 5800

 FEMME-logo

FEMME: A Randomised trial of treating Fibroids with either Embolisation or Myomectomy to Measure the Effect on quality of life, among women wishing to avoid hysterectomy: the FEMME study

Speciality: Reproductive Health

Chief Investigator: Professor Klim McPherson

Funded By: NIHR HTA     Portfolio Study ID: 11877

Phase: Phase III     

Initial Target Number of Patients: 224

 FOxTROT

FOxTROT:  Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy for patients with high-risk, operable colon cancer

Speciality: Colorectal

Chief Investigator: Professor Dion Morton

Funded By: CRUK     Portfolio Study ID: 3771

Phase: Phase III      

Initial Target Number of Patients: 1050 

IIH-WT-logo

IIH:WT:  is a randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension

Speciality: Neurological

Chief Investigator: Dr Alexandra Sinclair

Funded By: NIHR     Portfolio Study ID: 16025

Phase: Phase III      

Initial Target Number of Patients: 60

 
Neo-Excel Logo.jpg

NEO-EXCEL: Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer

Speciality: Breast Cancer

Chief Investigator: Professor Daniel Rea

Funded By: CRUK     Portfolio Study ID: 1729

Phase: Phase III      

Initial Target Number of Patients: 256

 NOSTRA Logo

NOSTRA: Can patients with residual cancer after chemotherapy for early breast cancer be identified with multiple ultrasound-guided biopsies?

Speciality: Breast Cancer              

Chief Investigator: Professor Daniel Rea

Funded By: CRUK / Roche      Portfolio Study ID: 38071

Phase: Phase III                        

Initial Target Number of Patients: 150

 LORIS%20Trial%20Logo%20Resized

LORIS:  A  trial comparing surgery with active monitoring for low risk DCIS

Speciality: Breast Cancer

Chief Investigator: Dr Matthew Wallis

Funded By: NIHR HTA     Portfolio Study ID: 16736

Phase: Phase III

Initial Target Number of Patients: 932

 ROCkeTS-Logo 100 pixels wide

ROCkeTS: Refining Ovarian Cancer Test Accuracy Scores: A test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer

Speciality: Gynaecology

Chief Investigator:  Mrs Sudha Sundar

Funded By: NIHR HTA     Portfolio Study ID: 17994

Phase: Diagnostic Test Accuracy Trial

Initial Target Number of Patients: 2450

ROSCO

ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo­adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy

Speciality: Breast Cancer

Chief Investigator: Professor Daniel Rea

Funded By: CRUK/Celgene     Portfolio Study ID: 19069

Phase: Phase III     

Initial Target Number of Patients: 1050

ROSSINI 2 Logo

ROSSINI 2: Reduction Of Surgical Site Infection using several Novel Interventions

Speciality: Colorectal

Chief Investigator: Professor Thomas Pinkney

Funded By: HTA     Portfolio Study ID: 39722

Phase: Phase III     

Initial Target Number of Patients: 6610

 SOCQER-2-Logo

SOCQER-2: Quality of Life Study in Patients Undergoing Surgery for Ovarian Cancer

Speciality: Gynaecology Cancer

Chief InvestigatorMrs Sudha Sundar

Funded By: NICE  Portfolio Study ID: 19553

Initial Target Number of Patients: 120

SMALL Logo

SMALL: Surgery versus Minimally invasive vacuum-Assisted excision for small screen-detected breast cancer – a phase III randomised multi-centre trial

Speciality: Breast Cancer   

Chief Investigator: Mr Stuart McIntosh

Funded By: HTA     Portfolio Study ID: 12240119 

Phase: Phase III          

Initial Target Number of Patients: 801

 
STAR-TREC

STAR-TREC:  Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?

Speciality: Colorectal     

Chief Investigator: Mr Simon Bach

Funded By: CRUK     Portfolio Study ID: 31203

Phase: Phase III     

Initial Target Number of Patients: 120

 STOP-Colitis logo

STOP-Colits Pilot Trial: A prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis.

Speciality: Gastroenterology

Chief Investigator: Professor Tariq Iqbal

Funded By: EME / NIHR     Portfolio Study ID: 35522

Phase: Phase III (Pilot)          

Initial Target Number of Patients: 30

sunrrise logo

SUNRRISE: Single use negative pressure dressing for reduction in surgical site infection following emergency laparotomy

Speciality: IBD

Chief Investigator: Mr Richard Wilkin

Funded By: RfPB     Portfolio Study ID: 36516

Phase: Phase III

Initial Target Number of Patients: 630

 
 TREC logo

TREC:  Transanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal Cancer

Speciality: Colorectal     

Chief Investigator: Mr Simon Bach

Funded By: CRUK     Portfolio Study ID: 7589

Phase: Phase III     

Initial Target Number of Patients: 46

 Wisteria Logo

WISTERIA: WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Speciality: Head and Neck    

Chief Investigator: Professor Hisham Mehanna

Funded By:  NAC, ECMS/AZ Alliance     Portfolio Study ID: 32918

Phase:  Phase I   

Initial Target Number of Patients: 42